Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 3,870,000 shares, a decrease of 17.0% from the December 15th total of 4,660,000 shares. Based on an average trading volume of 1,690,000 shares, the short-interest ratio is presently 2.3 days.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. D. Boral Capital reiterated a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, January 8th. HC Wainwright upped their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a report on Thursday, December 12th. Finally, B. Riley reaffirmed a “buy” rating and issued a $6.00 target price on shares of Trevi Therapeutics in a research note on Monday, October 7th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $9.31.

Institutional Investors Weigh In On Trevi Therapeutics

A number of institutional investors have recently modified their holdings of the company. Ally Bridge Group NY LLC acquired a new position in Trevi Therapeutics during the 2nd quarter worth about $4,395,000. Logos Global Management LP lifted its position in shares of Trevi Therapeutics by 27.3% during the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after purchasing an additional 600,000 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Trevi Therapeutics in the third quarter valued at approximately $409,000. Geode Capital Management LLC boosted its stake in shares of Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after purchasing an additional 117,418 shares during the period. Finally, Fred Alger Management LLC acquired a new position in shares of Trevi Therapeutics in the third quarter valued at approximately $256,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Stock Up 0.3 %

TRVI stock traded up $0.01 during mid-day trading on Thursday, hitting $3.83. 103,628 shares of the company were exchanged, compared to its average volume of 575,325. Trevi Therapeutics has a 12-month low of $1.27 and a 12-month high of $4.68. The firm has a market capitalization of $294.41 million, a P/E ratio of -8.70 and a beta of 0.87. The business has a fifty day simple moving average of $3.46 and a 200-day simple moving average of $3.17.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the previous year, the firm earned ($0.08) EPS. Research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.